RJA
BIOC

Raymond James & Associates’s Biocept, Inc. BIOC Stock Holding History

Raymond James & Associates’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3
Closed -$5K – 3743
2018
Q2 		$5K Hold
3
– – ﹤0.01% 3551
2018
Q1 		$7K Hold
3
– – ﹤0.01% 3420
2017
Q4 		$17K Hold
3
– – ﹤0.01% 3354
2017
Q3 		$31K Hold
3
– – ﹤0.01% 3278
2017
Q2 		$37K Buy
3
+1
+50% +$14.1K ﹤0.01% 3205
2017
Q1 		$45K Buy
+2
New +$34K ﹤0.01% 3151

Other funds holding BIOC

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Raymond James & Associates's BIOC Position: Q3 2018 in Review

Raymond James & Associates sold out of Biocept, Inc. (BIOC) in Q3 2018, closing a stake of 3 shares — an estimated $5K sold.

Raymond James & Associates first reported a position in BIOC in Q1 2017 and held it in 6 quarters. The position peaked at $45K in Q1 2017. 8 funds tracked by Wall St. Rank hold BIOC as of Q3 2018.

  • Raymond James & Associates reported no remaining Biocept, Inc. position as of Q3 2018 after selling out during the quarter.
  • Raymond James & Associates sold 3 Biocept, Inc. shares in Q3 2018, an estimated $5K.
  • Raymond James & Associates first reported a position in Biocept, Inc. in Q1 2017 and held it in 6 quarters.
  • Raymond James & Associates's Biocept, Inc. position peaked at $45K in Q1 2017.
  • 8 funds tracked by Wall St. Rank held Biocept, Inc. as of Q3 2018.

Based on Raymond James & Associates's 13F filing for Q3 2018, filed 14 Nov 2018.